The finding published on-line as an immediate early publication in "Cell Stem Cell" (Sept. 6. 2007) builds on the strategic breakthrough reported by Shinya Yamanaka. MD. PhD in 2006 and confirmed in the move of 2007 both by Yamanaka's aggroup and in independent studies by scientists at MIT. Harvard and UCLA.
The go by the UCSF aggroup should deepen investigate aimed at improving the original strategy the aggroup says and change magnitude its potential use for studying disease development and creating patient-specific stem-cell based therapies.
The bring home the bacon is the prove of a collaboration between the labs of Miguel Ramalho-Santos. PhD and Robert Blelloch. MD. PhD of the UCSF Institute for Regeneration Medicine.
"The new technique removes a study technical hurdle that has likely discouraged many labs around the world from carrying out studies on the strategy," says senior author Ramalho-Santos a UCSF Fellow and a member of the Diabetes bear on. For displace reasons he says removal of the overleap increases the technique's potential use in developing patient-specific cellular therapies.
"Now laboratories will be able to use the come to chew over a broad range of normal and diseased cells of arouse," says the first author of the study. Blelloch an assistant professor of urology. "There ordain be a much greater ability to precisely dissect the mechanisms of reprogramming and to identify the genes that ordain be most effective in transforming adult cells."
Yamanaka's strategy -- over-expressing certain genes in mouse skin cells to create reprogramming - relied on the insertion of a foreign "medicate resistance" gene into the walk skin cells. This gene would "switch on" in those cells that successfully converted to embryonic originate in cells thus providing a means of detecting them. The drawbacks of this technique were that it was technically difficult to displace out and because it involves a foreign gene would increase safety concerns that would keep its use in cell-based therapies.
In the current study the UCSF scientists developed an alternative to this genetically engineered "change by reversal" technique. They developed serum-free conditions in the cell grow dish that both promoted more successful reprogramming and generated embryonic originate in cells that could be detected based on their form and structure alone.
Scientists are interested in reprogramming because of its potential for developing human embryonic stem cells that include the genetic makeup of individual patients. In theory any patient's cell say a skin cell could be reprogrammed. If the resulting embryonic originate in cell could then be prompted in the culture cater to alter into one of the various cell types of the be such as of the heart lung and hit the resulting cells could give the starting point for a entertain of clinical-research strategies.
Researchers could create dopamine-producing cells from Parkinson's disease patients and chew over them in the culture dish to hit the books the earliest steps of disease development. They could also evaluate experimental drugs on such cells in the grow cater.
Alternatively they could generate healthy specialized cells from patients who had donated their genetic material and displace them into tissues -- without the assay of prompting immune rejection -- to interact failing hearts neurological diseases such as Parkinson's disease and amyotrophic lateral sclerosis spinal heap injury and diabetes.
The reprogramming strategy pioneered by Yamanaka -- who in August began his convert from Kyoto University to the UCSF-affiliated Gladstone initiate of Cardiovascular Disease and UCSF -- involved over-activating four genes in walk climb cells in the grow cater. His team showed that over-expressing these genes - oct4 sox2 klf4 and c-myc - can create the beat balance of genes in walk cells to suffer their adult functions and begin functioning as they would have as embryonic originate in cells. Yamanaka named these cells "induced pluripotent (iPS) cells."
But because only a very low percentage of cells end reversion to the embryonic originate in cell express with this technique and because the cells are situated among millions of cells in the culture dish that do not end the transformation the scientists had a difficult measure identifying the fully reprogrammed cells. Thus they developed the technique of inserting the foreign "drug-resistance" gene into the walk skin cells. This gene was designed to only "change by reversal on" in cells that completed the reversion to the embryonic stem cell state. With addition of the medicate to the culture dish the vast majority of cells those that had not reverted to embryonic stem cells died. Only those that had reverted survived and could then be expanded.
With the alternative technique developed by the UCSF aggroup the efficiency of embryonic stem cell production remained low. However the walk skin cells that did go away to change by reversal to embryonic originate in cells could readily be identified by their create and coordinate in the absence of any medicate. The researchers went on to show that these cells indeed behaved desire embryonic stem cells and could furnish rise to all cell types of the be.
Separately the aggroup demonstrated that reprogramming could be achieved when one of the four genes over-expressed to initiate reprogramming -- c-myc -- was replaced with a related gene known as n-myc. These genes are involved in the formation of different tumors so by beginning to replace genes in this method the researchers may find combinations of reprogramming genes that are safer says Blelloch.
"Studies should address the relative efficacy of n-myc versus c-myc in reprogramming and whether n-myc reactivation like c-myc results in tumor formation," he says.
An ongoing limitation of the Yamanaka method notes Blelloch is that it requires viral-mediated integration of four foreign genes - so-called transgenes. The goal would be to add the genes only temporarily or to use chemical compounds that could copy the cause of the genes in the cells. This will be a key focus of ongoing studies he says.
The biggest overleap of cover says Ramalho-Santos ordain be translating the methods from the mouse to human cells a affect that could take years. Researchers around the world including Ramalho-Santos. Blelloch and Yamanaka are working intently on this contend.
"It's a very exciting time in stem cell biology as exemplified in the studies of reprogramming," says Ramalho-Santos. "It's fascinating enough that an embryonic stem cell can give go to all cell types of the be. But that's what embryonic originate in cells do. They change and in the end furnish go to the whole organism.
"But taking back a differentiated cell to the embryonic originate in cell express - that's truly mesmerizing. It goes against the flow of development -- and yet we can do it. And we're getting easier technical ways to do it."
Forex Groups - Tips on Trading
Related article:
http://www.news-medical.net/?id=29724
comments | Add comment | Report as Spam
|
